Dyadic appoints Joe Hazelton as President; strategic shift to ancillary proteins with commercial partnerships

DYADIC INTERNATIONAL INC

Hazelton promoted to President, continues as COO; base salary raised 10% to $320,000; 25,000-share option grant with 4-year vesting.
Strategic pivot to ancillary recombinant proteins for life sciences, nutrition, and industrial markets; validated by partnerships with Proliant Health, dairy enzyme firm, and EN3ZYME.
Legacy biopharma programs remain active under CEO Emalfarb; company to pursue corporate rebranding.
CEO states milestones validate strategy; Hazelton to scale commercialization and drive operational execution.

item 5.02item 5.03item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Joseph Hazelton

President

DYAI · DYADIC INTERNATIONAL INC

Effective: 2025-05-29
Filed: Jun 02, 2025 23:59 UTC

On May 29, 2025, the board of directors (the "Board") of Dyadic International, Inc. (the "Company") appointed Joseph Hazelton as President of the Company.

Source: SEC EDGAR

accession 0001437749-25-019177

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.